TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, Pharmacokinetics and Immunogenicity Study of Abatacept Administered Intravenously to Treat Active Polyarticular-course Juvenile Idiopathic Arthritis in Japan

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who have a history of an inadequate therapeutic response or intolerance in the opinion of the examining physician to at least one biologics or Methotrexate (MTX).~* Diagnosis of Juvenile Idiopathic Arthritis (JIA) by International League of Associations for Rheumatology (ILAR) criteria as oligoarticular, polyarticular Rheumatoid Factor (RF+), polyarticular (RF-), or systemic with a polyarticular-course.~* Men and women, ages 4 to 17 years, inclusive at enrollment.~* Subjects must have a history of at least 5 joints with active disease and must have currently active articular disease as defined by:~  1. ≥2 active joints (e.g. presence of swelling, or if no swelling is present, limitation of motion (LOM) accompanied by pain, tenderness, or both) at screening and at Week 0 (Day 1).~ 2. ≥2 joints with LOM at screening and at Week 0 (Day 1).~Exclusion Criteria:~* Systemic onset JIA with any of the following manifestations within the last 6 months prior to enrollment: intermittent fever due to JIA, rheumatoid rash, hepatosplenomegaly, pleuritis, pericarditis, or macrophage activation syndrome.~* Presence of any other rheumatic disease or major chronic infectious/inflammatory/immunologic disease (e.g. inflammatory bowel disease, psoriatic arthritis, spondyloarthropathy, hypogammaglobulinemia, or systemic lupus erythematosus, etc.)

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Abatacept (Type: EXPERIMENTAL): Abatacept 10 mg/kg (for body weight less than 75 kg), 750 mg (for body weight between 75 and 100 kg), and 1g (for body weight above 100kg) intravenous infusion on Week 0 (Day 1), Week 2 (Day 15), Week 4 (Day 29) and every 4 weeks (28 days) thereafter up to the end of the study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Within-subject Variability of Insulin Detemir in Children and Adolescents With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 diabetes for at least 12 months~* Body mass index (BMI) for children (6 to 12 years): 15-20 kg/m\^2 (both inclusive)~* Body mass index (BMI) for adolescents (13 to 17 years): 18-25 kg/m\^2 (both inclusive)~* HbA1c (glycosylated haemoglobin) below 11.0% according to central laboratory results~* Current treatment with insulin at least twice daily~Exclusion Criteria:~* Any significant disease such as endocrine, hepatic, renal, cardiac, neurological, malignant, or pancreatic disease other than diabetes~* Receipt of any investigational product within the last four weeks~* Known or suspected allergy to trial products or related products

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Insulin detemir (Type: EXPERIMENTAL): None
- Insulin glargine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Targeting Pathways in Polycystic Ovary Syndrome (PCOS) Using Metformin (MET)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index (BMI) greater than or equal to 25~* Polycystic Ovary Syndrome criteria of both oligomenorrhea (\<9 menses per year) and androgen excess \[clinical hirsutism (Ferriman-Gallway score \>8 or severe acne) or elevated testosterone\].~* Taking no medications for the treatment of insulin resistance.~Exclusion Criteria:~* Diagnosis of Cushing's syndrome~* Untreated hypo/hyperthyroidism~* Elevated prolactin~* Congenital adrenal hyperplasia~* Renal insufficiency (creatinine \> 1.5)~* Diabetes~* Medications that can significantly affect endothelial function~* Pregnancy~* Breast Feeding~* Taking oral contraceptives~* Currently smoking

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Metformin (Type: EXPERIMENTAL): Metformin 500 mg. extended release (taken orally) one tablet with evening meal for one week, one tablet with morning and evening meal for one week, and one tablet at all three meals for the next three months.
- Delayed Start Metformin (Type: OTHER): After baseline study visit, this arm will return after three months without metformin for a repeat of the baseline study visit prior to initiating metformin 500 mg. extended release (taken orally) one tablet with evening meal for one week, one tablet with morning and evening meal for one week, and one tablet at all three meals for the next three months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of CNTO 148 Subcutaneous Injection Compared With Placebo in Patients With Active Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of RA according to the American College of Rheumatology criteria for at least 3 months prior to screening~* Have active Rheumatoid Arthritis at the time of screening and at baseline, as defined by 6 or more swollen joints and 6 or more tender joints and additional laboratory criteria~Exclusion Criteria:~* Have other inflammatory diseases, including but not limited to ankylosing spondylitis, systemic lupus erythematosus, Lyme disease~* Received disease-modifying antirheumatic drugs (\[DMARDs\] eg, D penicillamine, hydroxychloroquine, chloroquine, oral or parenteral gold, interleukin \[IL\]-1 receptor antagonist \[anakinra\], azathioprine, sulphasalazine, agents other than MTX) within 4 weeks prior to the first study dose

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Golimumab (CNTO 148) with Methotrexate (MTX) (Type: EXPERIMENTAL): None
- Infliximab with MTX (Type: EXPERIMENTAL): None
- Placebo with MTX (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* regular menstrual cycle~* 1 or more failed IVF attempts with poor response~* 5 or fewer oocytes retrieved~* FSH\>12 IU/l on day 3~Exclusion Criteria:~* PCOS~* Normal responders

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Participant requires immunoglobulin treatment for primary immunodeficiency disease (PIDD)~2. Participant age is compatible with local package insert requirements~3. Participant has been prescribed or has started treatment with HYQVIA (Immune Globulin (Human) 10% with rHuPH20)~4. Participant is willing and able to comply with the requirements of the protocol.~5. Female participant of child-bearing potential agrees to inform the investigator if she becomes pregnant, or plans to become pregnant during the course of the study~Exclusion Criteria:~1. Participant has known hypersensitivity to any of the components of the medicinal product~2. Participant has participated in an interventional clinical study involving a medicinal product or device within 30 days prior to enrollment or is scheduled to participate in an interventional clinical study involving a medical product or device during the course of this study~3. Participant is a family member or employee of the investigator~4. Participant is planning to become pregnant, pregnant or breastfeeding at the time of enrollment

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HYQVIA- Epoch 1 (Type: None): Participants receiving HYQVIA
- HYQVIA- Epoch 2 (Type: None): Participants with rHuPH antibody titers ≥160 (tested in Epoch 1)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ramipril in Pediatric Patients on Hemodialysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients \< 16 years old~* Patients who have been on regular HD for 6 months or longer~* Hypertension at enrollment~Exclusion Criteria:~* History of active connective tissue disease~* Acute infection within 1 month prior to the study~* Advanced liver disease~* Gastrointestinal dysfunction requiring parental nutrition or active malignancy~* Use of medications such as immunosuppressive drugs within 1 month prior to the study~* Use of anti-inflammatory medications~* Use of vitamin E at a dose higher than 60 IU per day or vitamin C higher than 500 mg per day~* History of myocardial infarction or cerebrovascular event within 3 months prior to the study~* History of ACE inhibitor-associated angioedema~* Inability to discontinue ACE inhibitors or ARBs

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Ramipril (Type: EXPERIMENTAL): Ramipril, 2.5 mg daily, administered orally for 16 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, matched for the interventional drug, administered orally, daily for 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Morphine for Treatment of Dyspnea in Patients With COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of COPD according to the current Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (GOLD);~* Optimal pharmacological treatment, including including treatment with a combination of a long-acting muscarinic antagonist and an ultra-long-acting β-agonist;~* Grade 3 or 4 dyspnea on the mMRC dyspnea scale;~* Optimal non-pharmacological treatment defined as completed a comprehensive pulmonary rehabilitation program.~Exclusion Criteria:~* History of substance misuse;~* Exacerbation of COPD within two weeks of study enrolment;~* Waiting list for lung transplantation;~* Pregnant or childbearing potential not using contraception;~* Renal failure (creatinine clearance \<15mL/min);~* Not being able to read or fill in the questionnaires or diary;~* Allergy for morphine or its excipients;~* Concomitant use of irreversible MAO blockers;~* Use of opioids;~* History of convulsions;~* Head injury;~* Intestinal obstruction;~* Gastroparesis;~* Liver disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- intervention (Type: ACTIVE_COMPARATOR): sustained release morphine
- control (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age equal to or greater than 18 years, with chronic genotype 1 HCV infection~* HCV RNA ≥ 10,000 IU/mL at screening~* Prior virological failure after treatment with pegylated interferon (PEG-IFN), RBV and a protease inhibitor following documented prior virology failure after treatment with a PEG-IFN + RBV regimen~* Evidence of cirrhosis~* Screening laboratory values within defined thresholds~* Use of two effective contraception methods if female of childbearing potential or sexually active male~Exclusion Criteria:~* Pregnant or nursing female or male with pregnant female partner~* Current or prior history of clinical hepatic decompensation~* Prior exposure to approved or experimental HCV specific direct-acting antivirals other than a nonstructural protein (NS)3/4A protease inhibitor~* History of solid organ transplantation, including liver transplant~* Hepatocellular carcinoma or other malignancy (with exception of certain resolved skin cancers)~* Chronic use of systemic immunosuppressive agents~* History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LDV/SOF (Type: EXPERIMENTAL): LDV/SOF FDC tablet plus placebo to match RBV for 24 weeks
- LDV/SOF + RBV (Type: EXPERIMENTAL): Placebo to match SOF/LDV FDC plus placebo to match RBV for 12 weeks, followed by LDV/SOF FDC plus RBV for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hypertension Prevention in Pre-Hypertensive Individuals

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* individuals with 30 to 70 years of age with pre-hypertension~Exclusion Criteria:~* low life expectancy~* other indications for the use of diuretics, such as cardiovascular disease~* intolerance to the study drugs~* pregnancy

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): None
- chlortalidone-amiloride (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Atrial Fibrillation Following Esophagectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females over the age of 40~* Scheduled to undergo esophagectomy~Exclusion Criteria:~* History of atrial fibrillation~* Prior severe side effects from amiodarone~* Elevated liver enzymes \>3 times the upper limit of normal (UNL)~* Corrected QT interval \> 450 ms~* Receiving class Ia or class III antiarrhythmics

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Amiodarone (Type: EXPERIMENTAL): Intravenous amiodarone
- Control (Type: OTHER): Control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participant had a diagnosis of rheumatoid arthritis (RA) as defined by the 1987 revised American College of Rheumatology (ACR) classification criteria and/or the ACR/the European League against Rheumatism (EULAR) 2010 classification criteria (any duration since diagnosis)~* Participants with moderate to severe RA defined as a Disease Activity Score in 28 Joints (DAS28) Erythrocyte Sedimentation Rate (ESR) or DAS28 C-Reactive Protein (CRP) score \>3.2~* Biologically treatment naïve and initiated adalimumab at baseline visit, as per standard daily clinical practice~* Availability of clinical data of the previous 12 weeks prior to baseline~* Ability to self-complete participant questionnaires.~* Participants had signed the authorization (or informed consent where applicable) to disclose and use personal health information after having been prescribed adalimumab~Exclusion Criteria:~* Participants who were pregnant or breastfeeding at enrollment or wished to become pregnant in the next 24 weeks.~* Participation in any RA-related clinical trial at the time of enrollment, at baseline, or at any point during the past 24 weeks prior to baseline~* Participants, who in the clinician's view, may not have been able to accurately report their quality of life (QoL) or prior resource utilization~* Participants, who in the clinician's view, may not have been able to adhere to adalimumab therapy over 24 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Participants with RA receiving adalimumab (Type: None): 40 mg adalimumab via subcutaneous (SC) injection every other week (eow) for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Development and Preliminary Trial of a Brief, Portable Health Intervention for Rural Sexual Minority Emerging Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Self-identify as lesbian, gay, or bisexual~* Live in Washington county, Tennessee (TN), or any of its 6 contiguous counties in northeastern TN~* Have personal Internet access~* Hair at least 2cm in length~Exclusion Criteria:~* Failure to meet inclusion criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 29 Years
- Healthy Volunteers: t

Study Arms:
- Expressive Writing (EW) (Type: EXPERIMENTAL): Expressive Writing (EW) prompts individuals to write about personally stressful events, potentially enabling cognitive processing of unresolved, psychological and physiological stressors.
- Self-Affirmation (SA) (Type: EXPERIMENTAL): Self-Affirmation (SA) interventions prompt individuals to write advice to a (hypothetical) similarly stigmatized person regarding how best to cope with stigma-related stress. By affirming one's own stigmatized identity through the process of helping another similarly stigmatized person.
- Control (Type: PLACEBO_COMPARATOR): Participants randomly assigned to the control condition will be asked to write about what they have done since waking up that morning for 20 minutes across 3 consecutive days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete